Key Takeaway: Xenon Pharmaceuticals Inc. has announced its participation in the Stifel 2024 Virtual CNS Days event, scheduled for March 19, 2024. During this event, key executives, including the Chief Financial Officer and Chief Commercial Officer, will present insights on the company’s progress and pipeline. A live webcast of the presentation will be accessible on Xenon’s website, with a replay available afterward.
Price reaction · baseline $44.37 (2024-03-11 close) · hit after-hours · clean, no other XENE news in the window
day 0 close · peak
-0.3%
Market Sentiment Analysis
POSITIVE FACTORS
Xenon Pharmaceuticals is actively participating in a notable industry event.
The company is focused on developing innovative therapies for neurological disorders.
They have a commitment to addressing high unmet medical needs.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+56%
120-day peak, hindsight
Typical move
14.4%
average across 4 past catalysts
Cash runway
~39 mo
Minimal dilution risk
Lead asset
XPF-001
Phase 1 · Primary Erythromelalgia
Full Press Release Details
VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Stifel 2024 Virtual CNS Days event.
Company Fireside Chat Presentation Details:
Date:
Tuesday, March 19, 2024
Time:
12:30-12:55 PM Eastern Time
Webcast:
Register here
Presenters:
Sherry Aulin, Chief Financial Officer
Chris Von Seggern, Chief Commercial Officer
A live webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.